Sylentis announces top-line results from Phase II study for RNAi drug in Glaucoma

(Pharmamar) The SYLTAG study, which includes 184 patients with a baseline IOP greater than or equal to 23 mm Hg, evaluates the efficacy and safety of four doses 0.375 percent (150 micrograms); 0.75 percent (300 micrograms); 1.125 percent (450 micrograms) y 1.5 percent (600 micrograms) given once a day for 28 days. The comparator group received timolol (0.5 percent), given twice a day.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news